SIC
PTCT icon

SJS Investment Consulting’s PTC Therapeutics PTCT Stock Holding History

SJS Investment Consulting’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31K Buy
16
+4
+33% +$289 ﹤0.01% 1936
2026
Q1 		$818 Buy
12
+1
+9% +$71 ﹤0.01% 1559
2025
Q4 		$836 Buy
11
+4
+57% +$291 ﹤0.01% 1359
2025
Q3 		$430 Hold
7
– – ﹤0.01% 1282
2025
Q2 		$342 Sell
7
-5
-42% -$237 ﹤0.01% 1227
2025
Q1 		$612 Sell
12
-1
-8% -$50 ﹤0.01% 1177
2024
Q4 		$587 Buy
13
+2
+18% +$86 ﹤0.01% 1190
2024
Q3 		$409 Hold
11
– – ﹤0.01% 1382
2024
Q2 		$337 Buy
11
+4
+57% +$130 ﹤0.01% 1409
2024
Q1 		$204 Hold
7
– – ﹤0.01% 1482
2023
Q4 		$193 Buy
7
+3
+75% +$69 ﹤0.01% 1465
2023
Q3 		$90 Sell
4
-2
-33% -$74 ﹤0.01% 1554
2023
Q2 		$245 Hold
6
– – ﹤0.01% 1366
2023
Q1 		$291 Buy
6
+4
+200% +$183 ﹤0.01% 1290
2022
Q4 		$76 Buy
2
+1
+100% +$42 ﹤0.01% 1512
2022
Q3 		$0 Buy
+1
New +$49 ﹤0.01% 1446

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

SJS Investment Consulting's PTCT Position: Q2 2026 in Review

SJS Investment Consulting increased its PTC Therapeutics (PTCT) stake by 33% in Q2 2026, buying an estimated $289 and bringing the position to 16 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1936.

SJS Investment Consulting first reported a position in PTCT in Q3 2022 and has held it in 16 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • SJS Investment Consulting held 16 shares of PTC Therapeutics worth $1.31K as of Q2 2026.
  • SJS Investment Consulting bought 4 PTC Therapeutics shares in Q2 2026, an estimated $289.
  • PTC Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1936 holding.
  • SJS Investment Consulting first reported a position in PTC Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.